A citation-based method for searching scientific literature

Justine A Barletta, Vânia Nosé, Peter M Sadow. Endocr Pathol 2021
Times Cited: 10







List of co-cited articles
45 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, Kevin Ebata, Brian B Tuch, Satoshi Yoda, Justin F Gainor, Lecia V Sequist,[...]. J Thorac Oncol 2020
107
40

Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.
Nishant Agrawal, Yuchen Jiao, Mark Sausen, Rebecca Leary, Chetan Bettegowda, Nicholas J Roberts, Sheetal Bhan, Allen S Ho, Zubair Khan, Justin Bishop,[...]. J Clin Endocrinol Metab 2013
147
40

Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing.
Raffaele Ciampi, Cristina Romei, Teresa Ramone, Alessandro Prete, Alessia Tacito, Virginia Cappagli, Valeria Bottici, David Viola, Liborio Torregrossa, Clara Ugolini,[...]. iScience 2019
58
40

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Samuel A Wells, Sylvia L Asa, Henning Dralle, Rossella Elisei, Douglas B Evans, Robert F Gagel, Nancy Lee, Andreas Machens, Jeffrey F Moley, Furio Pacini,[...]. Thyroid 2015
988
40


Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?
Marco Volante, Alfred K Lam, Mauro Papotti, Giovanni Tallini. Endocr Pathol 2021
17
30

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
216
30

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
685
30

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
877
30

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Vivek Subbiah, Mimi I Hu, Lori J Wirth, Martin Schuler, Aaron S Mansfield, Giuseppe Curigliano, Marcia S Brose, Viola W Zhu, Sophie Leboulleux, Daniel W Bowles,[...]. Lancet Diabetes Endocrinol 2021
77
30

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
V Subbiah, T Shen, S S Terzyan, X Liu, X Hu, K P Patel, M Hu, M Cabanillas, A Behrang, F Meric-Bernstam,[...]. Ann Oncol 2021
70
30

Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Xiao Shi, Cui-Wei Li, Li-Cheng Tan, Shi-Shuai Wen, Tian Liao, Yan Zhang, Tong-Zhen Chen, Ben Ma, Peng-Cheng Yu, Zhong-Wu Lu,[...]. J Clin Endocrinol Metab 2021
18
30

Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification.
Paula Soares, Antónia Afonso Póvoa, Miguel Melo, João Vinagre, Valdemar Máximo, Catarina Eloy, José Manuel Cameselle-Teijeiro, Manuel Sobrinho-Simões. Endocr Pathol 2021
11
20

Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance.
Elaine Kilgour, Dominic G Rothwell, Ged Brady, Caroline Dive. Cancer Cell 2020
133
20

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
S Filetti, C Durante, D Hartl, S Leboulleux, L D Locati, K Newbold, M G Papotti, A Berruti. Ann Oncol 2019
264
20

Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
Gilbert J Cote, Caitlin Evers, Mimi I Hu, Elizabeth G Grubbs, Michelle D Williams, Tao Hai, Dzifa Y Duose, Michal R Houston, Jacquelin H Bui, Meenakshi Mehrotra,[...]. J Clin Endocrinol Metab 2017
40
20

Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.
Paola Romeo, Carla Colombo, Roberta Granata, Giuseppina Calareso, Ambra Vittoria Gualeni, Matteo Dugo, Loris De Cecco, Maria Grazia Rizzetti, Angela Zanframundo, Antonella Aiello,[...]. Endocr Relat Cancer 2018
35
20

The role of microRNAs in the pathogenesis of thyroid cancer.
Soudeh Ghafouri-Fard, Zeinab Shirvani-Farsani, Mohammad Taheri. Noncoding RNA Res 2020
21
20

Update on Fundamental Mechanisms of Thyroid Cancer.
Alessandro Prete, Patricia Borges de Souza, Simona Censi, Marina Muzza, Nicole Nucci, Marialuisa Sponziello. Front Endocrinol (Lausanne) 2020
85
20

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Martin Schlumberger, Barbara Jarzab, Maria E Cabanillas, Bruce Robinson, Furio Pacini, Douglas W Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G Martins,[...]. Clin Cancer Res 2016
138
20

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Cristina Romei, Raffaele Ciampi, Rossella Elisei. Nat Rev Endocrinol 2016
175
20

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S Hong, Marwan G Fakih, John H Strickler, Jayesh Desai, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Timothy J Price, Adrian Sacher, Crystal S Denlinger,[...]. N Engl J Med 2020
580
20

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, Romel Somwar, Jennifer F Kherani, Jieun Son, Arrien A Bertram, Monika A Davare, Eric Gladstone, Elena V Ivanova,[...]. Clin Cancer Res 2021
46
20

PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.
Gloria Irene Manfredi, Alessandra Dicitore, Germano Gaudenzi, Michele Caraglia, Luca Persani, Giovanni Vitale. Endocrine 2015
77
20

Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4.
Vijay G Bhoj, Lucy Li, Kalpana Parvathaneni, Zheng Zhang, Stephen Kacir, Dimitrios Arhontoulis, Kenneth Zhou, Bevin McGettigan-Croce, Selene Nunez-Cruz, Gayathri Gulendran,[...]. Mol Ther Oncolytics 2021
10
20

Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
Ning Jin, Tianyun Jiang, David M Rosen, Barry D Nelkin, Douglas W Ball. Clin Cancer Res 2011
70
20

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
M Schlumberger, R Elisei, S Müller, P Schöffski, M Brose, M Shah, L Licitra, J Krajewska, M C Kreissl, B Niederle,[...]. Ann Oncol 2017
96
20

A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.
S M Lim, H Chang, M J Yoon, Y K Hong, H Kim, W Y Chung, C S Park, K H Nam, S W Kang, M K Kim,[...]. Ann Oncol 2013
94
20

RAS proto-oncogene in medullary thyroid carcinoma.
Margarida M Moura, Branca M Cavaco, Valeriano Leite. Endocr Relat Cancer 2015
58
20

RET revisited: expanding the oncogenic portfolio.
Lois M Mulligan. Nat Rev Cancer 2014
306
20

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.
T C Schneider, D de Wit, T P Links, N P van Erp, J J M van der Hoeven, H Gelderblom, T van Wezel, R van Eijk, H Morreau, H J Guchelaar,[...]. Int J Endocrinol 2015
36
20

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Steven I Sherman, Douglas O Clary, Rossella Elisei, Martin J Schlumberger, Ezra E W Cohen, Patrick Schöffski, Lori J Wirth, Milan Mangeshkar, Dana T Aftab, Marcia S Brose. Cancer 2016
57
20

Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Poupak Fallahi, Silvia Martina Ferrari, Maria Rosaria Galdiero, Gilda Varricchi, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Salvatore Benvenga, Alessandro Antonelli. Semin Cancer Biol 2022
30
20

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
20

Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.
Nicole M Iñiguez-Ariza, Sina Jasim, Mabel M Ryder, Ashish V Chintakuntlawar, John C Morris, Crystal R Hilger, Michael E Menefee, Robert C Smallridge, Nina J Karlin, Constanza Alcaino,[...]. J Clin Endocrinol Metab 2020
6
33

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
574
20

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Nikita Pozdeyev, Laurie M Gay, Ethan S Sokol, Ryan Hartmaier, Kelsi E Deaver, Stephanie Davis, Jena D French, Pierre Vanden Borre, Daniel V LaBarbera, Aik-Choon Tan,[...]. Clin Cancer Res 2018
217
20

Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Bin Xu, Talia Fuchs, Snjezana Dogan, Iñigo Landa, Nora Katabi, James A Fagin, R Michael Tuttle, Eric Sherman, Anthony J Gill, Ronald Ghossein. Thyroid 2020
64
20

Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions.
Agnieszka Maliszewska, Luis J Leandro-Garcia, Esmeralda Castelblanco, Anna Macià, Aguirre de Cubas, Gonzalo Goméz-López, Lucía Inglada-Pérez, Cristina Álvarez-Escolá, Leticia De la Vega, Rocío Letón,[...]. Am J Pathol 2013
31
20

Comprehensive Immune Profiling of Medullary Thyroid Cancer.
Nikita Pozdeyev, Timothy A Erickson, Lian Zhang, Kim Ellison, Christopher J Rivard, Sharon Sams, Fred R Hirsch, Bryan R Haugen, Jena D French. Thyroid 2020
18
20

The Molecular Signatures Database (MSigDB) hallmark gene set collection.
Arthur Liberzon, Chet Birger, Helga Thorvaldsdóttir, Mahmoud Ghandi, Jill P Mesirov, Pablo Tamayo. Cell Syst 2015
20

Detection of Molecular Alterations in Taiwanese Patients with Medullary Thyroid Cancer Using Whole-Exome Sequencing.
Ya-Sian Chang, Chun-Chi Chang, Hsi-Yuan Huang, Chien-Yu Lin, Kun-Tu Yeh, Jan-Gowth Chang. Endocr Pathol 2018
19
20

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Margarida M Moura, Branca M Cavaco, António E Pinto, Valeriano Leite. J Clin Endocrinol Metab 2011
153
20

Inferring tumour purity and stromal and immune cell admixture from expression data.
Kosuke Yoshihara, Maria Shahmoradgoli, Emmanuel Martínez, Rahulsimham Vegesna, Hoon Kim, Wandaliz Torres-Garcia, Victor Treviño, Hui Shen, Peter W Laird, Douglas A Levine,[...]. Nat Commun 2013
20

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
Dapeng Li, Yihebali Chi, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng,[...]. Clin Cancer Res 2021
19
20


The Pangenomic Classification of Pituitary Neuroendocrine Tumors: Quality Histopathology is Required for Accurate Translational Research.
Ozgur Mete, Shereen Ezzat, Arie Perry, Shozo Yamada, Silvia Uccella, Ashley B Grossman, Sylvia L Asa. Endocr Pathol 2021
7
14

What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics.
C Christofer Juhlin, Jérôme Bertherat, Thomas J Giordano, Gary D Hammer, Hironobu Sasano, Ozgur Mete. Endocr Pathol 2021
12
10

Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors.
Sylvia L Asa, Stefano La Rosa, Olca Basturk, Volkan Adsay, Marianna Minnetti, Ashley B Grossman. Endocr Pathol 2021
9
11

Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates.
José Manuel Cameselle-Teijeiro, Ozgur Mete, Sylvia L Asa, Virginia LiVolsi. Endocr Pathol 2021
8
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.